Neuropsychiatric drug development: Perspectives on the current landscape, opportunities and potential future directions.

Autor: Loiodice S; Karla Therapeutics SAS, Saint-Beauzire, France. Electronic address: simon.loiodice@karla-tx.com., D'Acquisto F; William Harvey Research Institute, School of Medicine and Dentistry, Queen Mary University of London, London, UK; School of Life and Health Science, University of Roehampton, London, UK., Drinkenburg P; Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, the Netherlands., Suojanen C; Broadreach Global LLC, Miami, FL, USA; European Brain Council, Brussels, Belgium., Llorca PM; Department of Psychiatry, CHU Clermont-Ferrand, University of Clermont Auvergne, CNRS, Clermont Auvergne INP, Institut Pascal (UMR 6602), Clermont-Ferrand, France; Fondation FondaMental, Créteil, France., Manji HK; Oxford University, Oxford, UK; Yale University, New Haven, CT, USA; UK Government Mental Health Mission, London, UK.
Jazyk: angličtina
Zdroj: Drug discovery today [Drug Discov Today] 2024 Nov 29; Vol. 30 (1), pp. 104255. Date of Electronic Publication: 2024 Nov 29.
DOI: 10.1016/j.drudis.2024.104255
Abstrakt: Mental health represents a major challenge to our societies. One key difficulty associated with neuropsychiatric drug development is the lack of connection between the underlying biology and the disease. Nevertheless, there is growing optimism in this field with recent drug approvals (the first in decades) and renewed interest from pharmaceutical companies and investors. Here we review some of the most promising drug discovery and development endeavors currently deployed by industry. We also present elements illustrating the renewed interest from key stakeholders in neuropsychiatric drug development and provide potential future directions in this field.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: